May 2007
Volume 48, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2007
Blood Brain Barrier Disruption Maculopathy
Author Affiliations & Notes
  • A. Galor
    Ophthalmology, Wilmer Eye Institute, Baltimore, Maryland
  • S. J. Ference
    Brain Tumor Institute,
    Cleveland Clinic, Cleveland, Ohio
  • A. D. Singh
    Cole Eye Institute,
    Cleveland Clinic, Cleveland, Ohio
  • M. S. Lee
    Department of Neuro-opthalmology, University of Minnesota, Minneapolis, Minnesota
  • G. H. J. Stevens
    Brain Tumor Institute,
    Cleveland Clinic, Cleveland, Ohio
  • V. L. Perez
    Ophthalmology,
    Cleveland Clinic, Cleveland, Ohio
  • D. M. Peereboom
    Brain Tumor Institute,
    Cleveland Clinic, Cleveland, Ohio
  • Footnotes
    Commercial Relationships A. Galor, None; S.J. Ference, None; A.D. Singh, None; M.S. Lee, None; G.H.J. Stevens, None; V.L. Perez, None; D.M. Peereboom, None.
  • Footnotes
    Support Research To Prevent Blindness
Investigative Ophthalmology & Visual Science May 2007, Vol.48, 5237. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      A. Galor, S. J. Ference, A. D. Singh, M. S. Lee, G. H. J. Stevens, V. L. Perez, D. M. Peereboom; Blood Brain Barrier Disruption Maculopathy. Invest. Ophthalmol. Vis. Sci. 2007;48(13):5237.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose:: To report on the development of visually significant maculopathy associated with blood brain barrier disruption therapy for the treatment of CNS lymphoma.

Methods:: Chart review of twenty patients undergoing blood brain barrier disruption therapy for treatment of CNS lymphoma at the Cleveland Clinic. Patients with documented maculopathy included in analysis.

Results:: Seven of thirteen patients (54%) were identified with new macular RPE changes after blood brain barrier disruption treatment which developed at a rate of 0.30 per person-year. The RPE changes consisted of fine clumps of hyperpigmentation in the foveal region associated with variable degrees of RPE loss. These changes were bilateral but often asymmetric. Two patients had decreased visual acuity due to maculopathy. One patient had documented progression of maculopathy after completion of treatment.

Conclusions:: Maculopathy is frequent after blood brain barrier disruption therapy.

Keywords: oncology • macula/fovea 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×